What Is Thymosin Beta-4? Benefits, Research & Safety

Thymosin Beta-4 was first isolated from the thymus gland in 1966 by Allan Goldstein at the Albert Einstein College of Medicine. The thymus, known for its role in T-cell maturation and immune function, was the source of numerous "thymosin" peptides believed to have immunological activity. Initial research in the 1970s and 1980s focused on potential immunological applications. However, the discovery that Thymosin Beta-4 was present in virtually all cell types—not just immune tissues—suggested broader biological functions. The breakthrough came with the identification of Thymosin Beta-4 as a major actin-sequestering protein in the early 1990s. This finding revealed its fundamental role in regulating cell structure and movement. Researchers found that Tβ4 binds to G-actin with high affinity, preventing premature polymerisation and allowing controlled cytoskeletal dynamics. Subsequent research in the late 1990s and 2000s demonstrated Thymosin Beta-4's remarkable wound healing properties. Studies showed accelerated wound closure, enhanced angiogenesis, and reduced inflammation in various injury models. The peptide entered clinical trials for several indications including wound healing, cardiac repair, and dry eye disease. RegeneRx Biopharmaceuticals developed Tβ4-based therapies including RGN-259 for ophthalmic use.